A61K 31/22 (20130101)
The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.
Weeber, Edwin J.; Ciarlone, Stephanie L.; and D'Agostino, Dominic P., "Ketone esters for treatment of angelman syndrome" (2016). USF Patents. 863.
University of South Florida